Inactive Instrument

Highlights CELLCEUTIX OTC Bulletin Board

Equities

CTIX

US15115V1017

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Feb. 01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
2023	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	Dec. 05	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 20	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	23-06-21	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	23-03-15	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-15	CI
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	22-12-13	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
INNOVATION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	22-06-15	AQ
Innovation Pharmaceuticals Inc. acquired an unknown minority stake in Squalus Medical.	22-06-14	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-13	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-14	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-09	CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-27	CI
Innovation Pharmaceuticals Provides Additional Information Regarding the Status of Its Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of Brilacidin for the Treatment of Moderate-To-Severe Covid-19 in Hospitalized Patients	21-08-12	CI
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting	21-07-22	CI
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium	21-06-18	CI
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19	21-06-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CELLCEUTIX OTC Bulletin Board

Equities

CTIX

US15115V1017

Highlights

Filters